Patient Derived Organoids to Advance Your Drug Development
Exploratory bioassays, validation services and advance drug screenings using our 3D tumor model
Physiologically Relevant 3D Tumor Models
Utilize our tumor organoid models. Our system uses proprietary culture methods developed in-house to generate physiologically relevant patient derived 3D tumor models from a wide range of cancer types. Our models support growth for both primary tumor and blood/pbmc samples via circulating tumor cells.
Patient-derived tumor organoids
Supports primary & blood/PBMC samples
Mirrors patient population heterogeneity
Actionable Insights from Patient-Derived Organoids
Our organoid platform provides researchers with clinically relevant data that bridges the gap between in vitro studies and patient outcomes. By testing compounds in patient-derived tumor models, we can generate insights into:
Drug potency and efficacy – measure therapeutic strength and response across diverse patient models.
In vivo validation – our organoids have been successfully engrafted in mice, where they grow into sizeable tumors. This enables direct comparison between organoid and animal studies, strengthening translational reliability.
This level of detail allows drug developers to predict real-world performance earlier in the pipeline, minimizing costly late-stage failures.
Circulating Tumor Cell Organoids: A Model for Metastatic Cancer
What Are CTCs?
Circulating tumor cells (CTCs) are malignant cells shed from a primary tumor into the blood or lymphatic system. While most are eliminated by immune defenses or mechanical stress, a small subset can survive, migrate into distant tissues, and form secondary tumors. Studying organoids derived from CTCs offers valuable insight into metastasis, treatment resistance, and disease progression.
Why CTCs Are Important
Our circulating tumor cell (CTC) organoid platform takes cancer modeling a step further by better representing metastatic disease. Unlike conventional models that rely on tissue from the primary tumor, CTC-derived organoids capture the unique biology of tumor cells that survive in the bloodstream and spread to distant sites. This makes them a powerful tool for drug discovery and testing therapies against advanced cancers.
